Dose of inj piptaz for endophthalmitis

Reading File

Searching the Web

piperacillin tazobactam intravitreal dose endophthalmitis

Finding Sources

Reading File

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC7574138

Here is a complete summary of the dosing for injection piperacillin-tazobactam (pip-taz) in endophthalmitis:

Inj. Piperacillin-Tazobactam for Endophthalmitis

1. Intravitreal Injection (Primary Route for Endophthalmitis)

Parameter	Details
Dose	225-250 mcg in 0.1 mL
Route	Intravitreal injection
Frequency	Repeat every 48 hours as needed
Coverage	Gram-negatives (especially Pseudomonas aeruginosa), Staphylococcus epidermidis, MDR organisms, Mycobacterium abscessus

The dose of 250 mcg/0.1 mL was used in a landmark animal study (PMID 15721618) comparing pip-taz vs ceftazidime in P. aeruginosa endophthalmitis - both were equally effective.
A published case report (PMC7574138) used 225 mcg/0.1 mL (repeated every 48 hours x 5 doses total) successfully in Mycobacterium abscessus endophthalmitis where all other agents were resistant.
Note: one case used 250 mcg/0.01 mL (a different smaller volume; likely a typo in the source - the standard preparation is 0.1 mL).

2. Systemic IV (Adjunct in Severe/Exogenous Endophthalmitis)

Indication	Dose
Standard adult dose	4.5 g (4g pip + 0.5g taz) IV every 6-8 hours
P. aeruginosa / serious infections	3.375 g IV every 6 hours or 4.5 g IV every 8 hours
Extended infusion (better PK/PD)	3.375 g IV over 4 hours every 8 hours

Adjust dose for renal insufficiency (GFR-based reduction).

Key Clinical Points

Pip-taz is NOT a first-line intravitreal antibiotic for routine endophthalmitis. The standard first-line intravitreal regimen remains vancomycin 1 mg/0.1 mL + ceftazidime 2.25 mg/0.1 mL (per Wills Eye Manual).
Pip-taz intravitreal is reserved as an alternative or adjunct when:
- Gram-negative (especially Pseudomonas) endophthalmitis is suspected/confirmed
- Organism is resistant to standard agents (e.g., MDR pathogens, Mycobacterium)
- Ceftazidime allergy or resistance
The intravitreal half-life data for pip-taz is not well established (shown as "NA" in published intravitreal antibiotic tables), so repeat dosing at 48 hours is guided by clinical response.

Sources:

Wills Eye Manual, 8th Ed. (Appendix 12 - Intravitreal Antibiotics)
Entokey - Intravitreal Antibiotics reference table
PMC Case Report: M. abscessus endophthalmitis treated with intravitreal pip-taz 225 mcg/0.1 mL
Experimental study (PMID 15721618): 250 mcg/0.1 mL effective in P. aeruginosa endophthalmitis

Inj Meropenem dose for endophthalmitis

Finding Sources

Searching the Web

meropenem intravitreal dose endophthalmitis mcg

Reading Web Page

https://moseye.org/wp-content/uploads/2022/10/Intravitreal-d…

Searching the Web

meropenem intravitreal injection endophthalmitis 100 mcg preparation protocol

Here is the complete dosing summary for meropenem in endophthalmitis:

Inj. Meropenem for Endophthalmitis

1. Intravitreal Injection

Parameter	Details
Dose	100 mcg in 0.1 mL
Vitreous half-life	~2.6 hours (posterior route of clearance)
Repeat frequency	Not well established - based on clinical response
When to use	MDR gram-negatives, non-responding cases, Pseudomonas, ESBL producers

Note: Meropenem is listed as an alternative/salvage agent for non-responding endophthalmitis, not a first-line drug. The Entokey intravitreal antibiotic reference table lists meropenem with a vitreous half-life of 2.6 h and posterior route of clearance, but notably the dose column is left blank in most published tables - indicating limited clinical standardization.

Important caveat: The intravitreal dose is not firmly standardized across guidelines. Some protocols list 100 mcg/0.1 mL based on extrapolation from experimental data. Always verify with your institutional pharmacy.

2. Systemic IV (Adjunct - for severe/exogenous endophthalmitis)

Indication	Dose	Frequency
Standard serious infections	1 g IV	Every 8 hours
Severe/MDR Pseudomonas, meningitis	2 g IV	Every 8 hours
Infusion time	Over 15-30 min (or extended infusion over 3-4 hours for better PK/PD)	-
Renal adjustment	Required if CrCl <51 mL/min	-

IV meropenem is particularly relevant in endophthalmitis because it achieves therapeutic vitreous concentrations when given systemically - making it a useful adjunct to intravitreal treatment in severe cases, to maintain antibiotic levels after intravitreal concentrations fall to subtherapeutic levels (PMC9954776).

Key Clinical Points

Meropenem intravitreally is a second-line / salvage agent used when:
- Standard regimen (vancomycin + ceftazidime) has failed
- MDR gram-negative organisms are confirmed/suspected
- Pseudomonas aeruginosa with ceftazidime resistance
- ESBL-producing organisms
The short intravitreal half-life of ~2.6 hours is a significant limitation - suggesting that systemic meropenem may actually be more practical to sustain vitreous drug levels than repeated intravitreal injections.
First-line intravitreal regimen remains: vancomycin 1 mg/0.1 mL + ceftazidime 2.25 mg/0.1 mL.

Sources:

Entokey - Intravitreal Antibiotics table (vitreous PK data)
Intravitreal Drugs in Endophthalmitis - Dr. Manish Bapayee protocol
PMC9954776 - systemic meropenem achieving therapeutic vitreous concentrations

This is a shared conversation. Sign in to Orris to start your own chat.